Glenmark unit clinches $700mn licensing deal for its cancer drug

Ichnos Glenmark Innovation (III), a US-based Glenmark unit, is conducting Faz-1 clinical studies for ISB 2001, the presence of a research to treat multiple myeloma with a kind of blood cancer. As part of the agreement, Abbvie will do and sell in North America, Europe, Japan and the Great China, and Glenmark protects the rights for India and developing markets.

“This asset is in the world standards; you do not encounter a first -class being very often for patients, which can change the landscape for patients, and the value of the agreement is entirely the quality of the data,” Glenmark’s CEO CEO, Glenmark’s CEO. He said.

According to Bloomberg Intelligence’s estimates, the Multiple myeloma treatment market is estimated to increase to approximately 33 billion dollars by 2030.

ISB 2001 targets cases where many patients do not respond to existing treatments or cancer returns. At the same time, it is a “three -specific” antibody that targets three different markers on cancer cells; This helps a patient to fight cancer, including other treatments, including those who use their T cells.

Both the FDA orphan medicine and the fast road appointments are given to ISB 2001 by emphasizing its potential. Early trial results are promising.

“This is a turning point for India… Basically, India puts India on the world map, Sal Saldanha said. “This is for bispecific antibodies between the first three to five agreements that have been globally cut in the last two years, Sal said Saldanha.

In 2025, Pfizer licensed the bispecific presence of 3SBIO up to $ 6 billion in a potential of $ 1.25 billion, and Bristol Myers Squibb licensed the existence of Biontch’s existence of $ 1.5 billion of $ 11.1 billion.

Following the license agreement, ABBVI will take over more development for FAZ-2 and FAZ-3 attempts before the file for regulatory approval. The process will typically take four to five years.

Glenmark shares closed 5.54% higher on Thursday. The agreement was announced after the closure of the trade of the day.

Saldanha said, “This has been a big journey for me personally and for Glenmark,” Saldanha said. In 2006, the company founded the first AR -GE New Biology Research Center in Switzerland and made a series of license agreements in the early years. In 2019, he returned the presence of RO -GE under the Ichnos Sciences, a new company based on the registered Beat Bispecific platform. In 2024, the duo announced that Ichnos Glenmark innovation (IGI) was formed.

Roopal Thakkar, Vice President, Research and Development and Chief Scientific Officer Abbvie said, Mul Multipassifics, including Trispecific antibodies, said the potential to give deeper, more durable answers in immuno-oncology at the same time.

Currently, there are no commercialized trispecific antibodies, Sal Saldanha said, but a few pharmaceutical companies are trying to improve them.

Saldanha said, iz We are among the pioneers, to verify the first men to develop a trispecific antibody and to show that it has a large security profile and activity. ” He said.

IgI will continue to develop very specific antibodies. There is an ISB 2301, which has another asset found in the discovery stages and other assets for application in solid tumors.

“ISB 2001, Beat Protein platform exemplifies the potential to produce effective multispecifics that can overcome the results of our Beat protein platform, which can overcome treatment and improve the results in difficult cancers.” He said.

Saldanha said, “We will continue to develop assets and move to a certain level, and we will continue to develop on our own or with a partner at a later stage,” Saldanha said.

Saldanha is to increase the value chain as Glenmark will continue to build on high -valuable assets. The basic dermatology in global markets will focus on respiratory and oncology segments.

Saldanha said that the company has no plan to pay for prepaid and milestone to pay.

Saldanha, “II, in terms of their research spends about 70 million dollars a year, so, this pre -payment is financed for the next three to four years. In addition, some of the amounts will return to Glenmark,” he said.